{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:44:38Z","timestamp":1794343478920,"version":"4.9.0"},"reference-count":61,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783540360278","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1007\/3-540-36028-x_11","type":"book-chapter","created":{"date-parts":[[2006,10,13]],"date-time":"2006-10-13T21:54:09Z","timestamp":1160776449000},"page":"335-350","source":"Crossref","is-referenced-by-count":1,"title":["Gene Therapy: Role in Myocardial Protection"],"prefix":"10.1007","author":[{"given":"A. S.","family":"Pachori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. G.","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. J.","family":"Dzau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"11_CR1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1073\/pnas.231619298","volume":"99","author":"C.L. Antos","year":"2002","unstructured":"Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton J, Richardson JA, Hill JA, Olson EN (2002) Activated glycogen synthase kinase 3-\u03b2 suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99:907\u2013912","journal-title":"Proc Natl Acad Sci USA"},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"II365","DOI":"10.1161\/01.CIR.92.9.365","volume":"92","author":"T. Asahara","year":"1995","unstructured":"Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM (1995) Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92:II365\u2013II371","journal-title":"Circulation"},{"key":"11_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nm0102-35","volume":"8","author":"M. Asakura","year":"2002","unstructured":"Asakura M, Kitakaze M, Taskashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumara Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S (2002) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8:35\u201340","journal-title":"Nat Med"},{"key":"11_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6","volume":"190","author":"D.L. Carden","year":"2000","unstructured":"Carden DL, Granger DN (2000) Pathophysiology of ischemia-reperfusion injury. Am J Pathol 190:255\u2013266","journal-title":"Am J Pathol"},{"key":"11_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/74651","volume":"6","author":"P. Carmeliet","year":"2000","unstructured":"Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389\u2013395","journal-title":"Nat Med"},{"key":"11_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0022-5223(98)70289-2","volume":"115","author":"E.P. Chen","year":"1998","unstructured":"Chen EP, Bittner HB, Davis RD, Van Trigt P, Folz RJ (1998) Physiological effects of extracellular superoxide dismutase transgene overexpression on myocardial function after ischemia and reperfusion injury. J Thorac Cardiovasc Surg 115:450\u2013458","journal-title":"J Thorac Cardiovasc Surg"},{"key":"11_CR7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/sj.gt.3301439","volume":"8","author":"H. Chen","year":"2001","unstructured":"Chen H, Mohuczy D, Li D, Kimura B, Phillips MI, Mehta P, Mehta JL (2001) Protection against ischemia\/reperfusion injury and myocardial dysfunction by antisenseoligodeoxynucleotide directed at angiotensin-converting enzyme mRNA. Gene Ther 8:804\u2013810","journal-title":"Gene Ther"},{"key":"11_CR8","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/sj.gt.3300994","volume":"6","author":"N. Chirmule","year":"1999","unstructured":"Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J (1999) Immune responses to adenovirus and adeno associated virus in humans. Gene Ther 6:1574\u20131583","journal-title":"Gene Ther"},{"key":"11_CR9","doi-asserted-by":"publisher","first-page":"15L","DOI":"10.1016\/S0002-9149(97)00845-X","volume":"80","author":"W.S. Colucci","year":"1997","unstructured":"Colucci WS (1997) Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 80:15L\u201325L","journal-title":"Am J Cardiol"},{"key":"11_CR10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1067\/mhj.2000.96469","volume":"139","author":"R.B. D\u2019Agostino","year":"2000","unstructured":"D\u2019Agostino RB, Russel MW, Huse DM, Ellison RC, Silbershantz H, Wilson PW, Hartz SC (2000) Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 139:272\u2013281","journal-title":"Am Heart J"},{"key":"11_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/jgm.619","volume":"6","author":"M.L. Edelstein","year":"2004","unstructured":"Edelstein ML, Abedi MR, Wixon J, Edelstein RM (2004) Gene therapy clinical trials worldwide 1989\u20132002\u2014an overview. J Gene Med 6:597\u2013602","journal-title":"J Gene Med"},{"key":"11_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0008-6363(97)00148-X","volume":"35","author":"L.J. Feldman","year":"1997","unstructured":"Feldman LJ, Steg G (1997) Optimal techniques for arterial gene transfer. Cardiovasc Res 35:391\u2013404","journal-title":"Cardiovasc Res"},{"key":"11_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005082-199601000-00002","volume":"10","author":"M. Funk","year":"1996","unstructured":"Funk M, Krumholz HM (1996) Epidemiologic and economic impact of advanced heart failure. J Cardiovasc Nurs 10:1\u201310","journal-title":"J Cardiovasc Nurs"},{"key":"11_CR14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/nm0596-534","volume":"2","author":"F.J. Giordano","year":"1996","unstructured":"Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O, Hammond HK (1996) Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 2:534\u2013539","journal-title":"Nat Med"},{"key":"11_CR15","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/S0140-6736(98)90017-4","volume":"352","author":"M.M. Givertz","year":"1998","unstructured":"Givertz MM, Colucci WS (1998) New targets for heart failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet 352:S134\u2013S138","journal-title":"Lancet"},{"key":"11_CR16","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1161\/hc1102.105595","volume":"105","author":"C.L. Grines","year":"2002","unstructured":"Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL (2002) Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105:1291\u20131297","journal-title":"Circulation"},{"key":"11_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/415234a","volume":"415","author":"J.M. Isner","year":"2002","unstructured":"Isner JM (2002) Myocardial gene therapy. Nature 415:234\u2013239","journal-title":"Nature"},{"key":"11_CR18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/0002-8703(91)90225-7","volume":"12","author":"W.B. Kannel","year":"1991","unstructured":"Kannel WB, Belanger AJ (1991) Epidemiology of heart failure. Am Heart J 12:951\u2013957","journal-title":"Am Heart J"},{"key":"11_CR19","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/S0003-4975(96)00946-0","volume":"62","author":"M.G. Kaplitt","year":"2000","unstructured":"Kaplitt MG, Xiao X, Samulski RJ, Li J, Ojamaa K, Klein IL, Makimura H, Kaplitt MJ, Strumpf RK, Diethrich EB (2000) Long term gene transfer in porcine myocardium after coronary infusion of and adeno-associated virus vector. Ann Thorac Surg 62:1669\u20131676","journal-title":"Ann Thorac Surg"},{"key":"11_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0955-2235(89)90012-4","volume":"1","author":"M. Klagsbrun","year":"1989","unstructured":"Klagsbrun M (1989) The fibroblast growth factor family: structural and biological properties. Prog Growth Factor Res 1:207\u2013235","journal-title":"Prog Growth Factor Res"},{"key":"11_CR21","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI119730","volume":"100","author":"Q. Li","year":"1997","unstructured":"Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, Kajstura J, Baerga R, Anversa P (1997) Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 100:1991\u20131999","journal-title":"J Clin Invest"},{"key":"11_CR22","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/01.CIR.103.14.1893","volume":"103","author":"Q. Li","year":"2001","unstructured":"Li Q, Bolli R, Qiu Y, Tang XL, Guo Y, French BA (2001) Gene therapy with extracellular super-oxide dismutase protects conscious rabbits against myocardial infarction. Circulation 103:1893\u20131898","journal-title":"Circulation"},{"key":"11_CR23","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1161\/01.CIR.98.25.2800","volume":"98","author":"D.W. Losordo","year":"1998","unstructured":"Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM (1998) Gene therapy for myocardial angiogenesis. Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800\u20132804","journal-title":"Circulation"},{"key":"11_CR24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0022-5223(98)70455-6","volume":"115","author":"C.A. Mack","year":"1998","unstructured":"Mack CA, Patel SA, Schwarz EA, Zanzonico P, Hahn RT, Hercil A, Devereux RB, Goldsmith SJ, Christian TF, Sanborn TA, Kovesdi I, Hackett N, Isom OW, Crystal RG, Rosengart J (1998) Biological bypass with the use of adenovirus-mediated transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 115:168\u2013177","journal-title":"J Thorac Cardiovasc Surg"},{"key":"11_CR25","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2165\/00003088-200241120-00001","volume":"41","author":"C. Mah","year":"2002","unstructured":"Mah C, Byrne BJ, Flotte TR (2002) Virus-based gene delivery systems. Clin Pharmacokinet 41:901\u2013911","journal-title":"Clin Pharmacokinet"},{"key":"11_CR26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1172\/JCI11459","volume":"106","author":"M.J. Mann","year":"2000","unstructured":"Mann MJ, Dzau VJ (2000) Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 106:1071\u20131075","journal-title":"J Clin Invest"},{"key":"11_CR27","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S0140-6736(99)09405-2","volume":"354","author":"M.J. Mann","year":"1999","unstructured":"Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, Orav EJ, Ehsan A, Dell\u2019Acqua G, Dzau VJ (1999) Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomized, controlled trial. Lancet 354:1493\u20131498","journal-title":"Lancet"},{"key":"11_CR28","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1161\/01.RES.0000019540.41697.60","volume":"90","author":"I. Masaki","year":"2002","unstructured":"Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, Nakagawa K, Hou X, Nagai Y, Hasegawa M, Sugimachi K, Sueishi K (2002) Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 90:966\u2013973","journal-title":"Circ Res"},{"key":"11_CR29","first-page":"1703","volume":"358","author":"M. McCarthy","year":"2001","unstructured":"McCarthy M (2001) Molecular decoy may keep bypass grafts open. Lancet 358:1703","journal-title":"Lancet"},{"key":"11_CR30","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1161\/01.CIR.0000014763.63528.9D","volume":"105","author":"J.C. McMurray","year":"2002","unstructured":"McMurray JC, Pfeffer MA (2002) New therapeutic options in congestive heart failure. Circulation 105:2099\u20132106","journal-title":"Circulation"},{"key":"11_CR31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0008-6363(99)00132-7","volume":"43","author":"J.L. Mehta","year":"1999","unstructured":"Mehta JL, Li DY (1999) Inflammation in ischemic heart disease: response to tissue injury or a pathogenic villain? Cardiovasc Res 43:291\u2013299","journal-title":"Cardiovasc Res"},{"key":"11_CR32","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1161\/hc0502.103363","volume":"105","author":"L.G. Melo","year":"2002","unstructured":"Melo LG, Agrawal R, Zhang L, Rezvani M, Mangi AA, Ehsan E, Griese DP, Dell\u2019Acqua G, Mann MJ, Oyama J, Yet SF, Layne MD, Perrella AM, Dzau VJ (2002) Gene Therapy strategy for long term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 105:602\u2013607","journal-title":"Circulation"},{"key":"11_CR33","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1096\/fj.03-1171rev","volume":"18","author":"L.G. Melo","year":"2004","unstructured":"Melo LG, Pachori AS, Kong D, et al (2004) Gene and cell-based therapies for heart disease. FASEB J 18:648\u2013663","journal-title":"FASEB J"},{"key":"11_CR34","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S1357-4310(00)01810-4","volume":"6","author":"P.E. Monahan","year":"2000","unstructured":"Monahan PE, Samulski RJ (2000) Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 6:433\u2013440","journal-title":"Mol Med Today"},{"key":"11_CR35","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/nm0897-894","volume":"3","author":"R. Morishita","year":"1997","unstructured":"Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T (1997) In vivo transfection of cis element \u201cdecoy\u201d against nuclear factor factor \u03baB binding sites prevents myocardial infarction. Nat Med 3:894\u2013899","journal-title":"Nat Med"},{"key":"11_CR36","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1038\/sj.gt.3301923","volume":"9","author":"T. Niidome","year":"2002","unstructured":"Niidome T, Huang L (2002) Gene therapy progress and prospects: non-viral vectors. Gene Ther 9:1647\u20131652","journal-title":"Gene Ther"},{"key":"11_CR37","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1161\/01.HYP.0000017827.63253.16","volume":"20","author":"A.S. Pachori","year":"2002","unstructured":"Pachori AS, Numan MT, Ferrario CM, Diz DM, Raizada MK, Katovich MJ (2002) Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. Hypertension 20:969\u2013975","journal-title":"Hypertension"},{"key":"11_CR38","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/S0003-4975(99)01073-5","volume":"68","author":"J.L. Park","year":"1999","unstructured":"Park JL, Lucchesi BR (1999) Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 68:1905\u20131912","journal-title":"Ann Thorac Surg"},{"key":"11_CR39","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0008-6363(00)00029-8","volume":"46","author":"J.T. Peterson","year":"2000","unstructured":"Peterson JT, Li H, Dillon L, Bryant JW (2000) Evolution of metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted heart. Cardiovasc Res 46:307\u2013315","journal-title":"Cardiovasc Res"},{"key":"11_CR40","first-page":"H1406","volume":"260","author":"J.M. Pfeffer","year":"1991","unstructured":"Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E (1991) Progressive ventricular remodelling in rat myocardial infarction. Am J Physiol 260:H1406\u2013H1414","journal-title":"Am J Physiol"},{"key":"11_CR41","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/00007890-199909270-00015","volume":"68","author":"R.S. Poston","year":"1999","unstructured":"Poston RS, Mann MJ, Hoyt EG, Ennen M, Dzau VJ, Robbins RC (1999) Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, non-toxic, highly efficient transfection method. Transplantation 68:825\u2013832","journal-title":"Transplantation"},{"key":"11_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0163-7258(98)00020-5","volume":"80","author":"P.D. Robbins","year":"1998","unstructured":"Robbins PD, Ghivizzani SC (1998) Viral vectors for gene therapy. Pharmacol Ther 80:35\u201347:1998","journal-title":"Pharmacol Ther"},{"key":"11_CR43","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.cardiores.2004.07.003","volume":"64","author":"F. Sharif","year":"2004","unstructured":"Sharif F, Daly K, Crowley J, O\u2019Brien T (2004) Current status of catheter-and stent-based gene therapy. Cardiovasc Res 64:208\u2013216","journal-title":"Cardiovasc Res"},{"key":"11_CR44","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1172\/JCI200113885","volume":"108","author":"C.A. Stein","year":"2001","unstructured":"Stein CA (2001) The experimental use of antisense oligonucleotides: a guide for the perplexed. J Clin Invest 108:641\u2013644","journal-title":"J Clin Invest"},{"issue":"Suppl 8A","key":"11_CR45","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1016\/S0002-9343(02)01084-7","volume":"112","author":"E.A. Stein","year":"2002","unstructured":"Stein EA (2002) Identification and treatment of individuals at high risk of coronary artery disease. Am J Med 112Suppl 8A:3S\u20139S","journal-title":"Am J Med"},{"key":"11_CR46","first-page":"304","volume":"2","author":"S.M. Stepkowski","year":"2000","unstructured":"Stepkowski SM (2000) Development of antisense oligodeoxynucleotides for transplantation. Curr Opin Mol Ther 2:304\u2013317","journal-title":"Curr Opin Mol Ther"},{"key":"11_CR47","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1161\/01.CIR.101.25.2981","volume":"101","author":"M.G. Sutton","year":"2000","unstructured":"Sutton MG, Sharpe N (2000) Left ventricular remodeling aftermyocardial infarction. Pathophysiology and therapy. Circulation 101:2981\u20132988","journal-title":"Circulation"},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1540-8183.2002.tb01026.x","volume":"15","author":"C. Sylven","year":"2002","unstructured":"Sylven C, Sarkar N, Insulander P, Kenneback G, Blomberg P, Islam K, Drvota V (2002) Catheter-based transendocardial myocardial gene transfer. J Interv Cardiol 15:7\u201313","journal-title":"J Interv Cardiol"},{"key":"11_CR49","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S0003-4975(99)00807-3","volume":"68","author":"J.F. Symes","year":"1999","unstructured":"Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, Isner JM (1999) Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 68:830\u2013837","journal-title":"Ann Thorac Surg"},{"key":"11_CR50","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1073\/pnas.97.3.1196","volume":"97","author":"T. Taigen","year":"2000","unstructured":"Taigen T, Windt LJ, Lim HW, Molkentin JD (2000) Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 97:1196\u20131201","journal-title":"Proc Natl Acad Sci USA"},{"key":"11_CR51","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1089\/10430349950016366","volume":"10","author":"R.A. Tio","year":"1999","unstructured":"Tio RA, Tkebuchava T, Scheurermann TH, Lebherz C, Magner M, Kearny M, Esakof DD, Isner JM, Symes JF (1999) Intramyocardial gene therapy with naked DNA encoding vascular endothelial growth factor improves collateral blood flow to ischemic myocardium. Hum Gene Ther 10:2953\u20132960","journal-title":"Hum Gene Ther"},{"key":"11_CR52","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/S0003-4975(99)00279-9","volume":"67","author":"H. Ueda","year":"1999","unstructured":"Ueda H, Sawa Y, Matsumoto K, Kitagawa-Sakakida S, Kawahira Y, Nakamura T, Kaneda Y, Matsuda H (1999) Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart. Ann Thorac Surg 67:1726\u20131731","journal-title":"Ann Thorac Surg"},{"key":"11_CR53","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1161\/01.ATV.17.11.2453","volume":"17","author":"H. Ueno","year":"1997","unstructured":"Ueno H, Li JJ, Masuda S, Qi Z, Yamamoto H, Takeshita A (1997) Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 17:2453\u20132460","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"11_CR54","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/jgm.287","volume":"4","author":"I. Vajanto","year":"2002","unstructured":"Vajanto I, Rissanen TT, Rutanen J, Hiltunen MO, Tuomisto TT, Arve K, Narvanen O, Manninen H, Rasanen H, Hippelainen M, Alhava E, Yla-Herttuala S (2002) Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med 4:371\u2013380","journal-title":"J Gene Med"},{"key":"11_CR55","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1161\/01.CIR.103.17.2138","volume":"103","author":"P.R. Vale","year":"2001","unstructured":"Vale PR, Losordo DW, Milliken CE, McDonald MC, Gravelin LM, Curry CM, Esakof DD, Maysky M, Symes JF, Isner JM (2001) Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 103:2138\u20132143","journal-title":"Circulation"},{"key":"11_CR56","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/nm0297-158","volume":"3","author":"J.H. Ware","year":"1997","unstructured":"Ware JH, Simons M (1997) Angiogenesis in ischemic heart disease. Nat Med 3:158\u2013164","journal-title":"Nat Med"},{"key":"11_CR57","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1172\/JCI11325","volume":"106","author":"R.R. White","year":"2000","unstructured":"White RR, Sullenger BA, Rusconi CP (2000) Developing aptamers into therapeutics. J Clin Invest 106:929\u2013934","journal-title":"J Clin Invest"},{"key":"11_CR58","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1172\/JCI11205","volume":"106","author":"R.S. Williams","year":"2000","unstructured":"Williams RS, Benjamin IJ (2000) Protective responses of the ischemic myocardium. J Clin Invest 106:813\u2013818","journal-title":"J Clin Invest"},{"key":"11_CR59","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","volume":"97","author":"P.W. Wilson","year":"1998","unstructured":"Wilson PW, D\u2019Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837\u20131847","journal-title":"Circulation"},{"key":"11_CR60","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1050-1738(00)00029-3","volume":"9","author":"D.M. Yellon","year":"2000","unstructured":"Yellon DM, Baxter GF (2000) Reperfusion injury revisited. Is there a role for growth factor signalling in limiting lethal reperfusion injury? Trends Cardiovasc Med 9:245\u2013249","journal-title":"Trends Cardiovasc Med"},{"key":"11_CR61","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nm0603-694","volume":"9","author":"S. Yla-Herttuala","year":"2003","unstructured":"Yla-Herttuala S, Alitalo K (2003) Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 9:694\u2013700","journal-title":"Nat Med"}],"container-title":["Handbook of Experimental Pharmacology","The Vascular Endothelium II"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/3-540-36028-X_11.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T21:01:03Z","timestamp":1619557263000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/3-540-36028-X_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[null]]},"ISBN":["9783540360278"],"references-count":61,"URL":"https:\/\/doi.org\/10.1007\/3-540-36028-x_11","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/3-540-36028-x","asserted-by":"object"}]},"subject":[]}}